What is Sparrow Pharmaceuticals?
Sparrow Pharmaceuticals is dedicated to advancing novel treatments for metabolic disorders, with a primary focus on its lead candidate, clofutriben. This HSD-1 inhibitor is engineered to modulate intracellular cortisol levels, offering a potential therapeutic avenue for patients with challenging forms of type 2 diabetes and associated metabolic complications. The company's strategic direction is centered on translating its scientific discoveries into impactful clinical solutions, addressing significant unmet needs within the biopharmaceutical landscape.
How much funding has Sparrow Pharmaceuticals raised?
Sparrow Pharmaceuticals has raised a total of $206.8M across 3 funding rounds:
Series A
$50M
Private Equity
$61.8M
Series B
$95M
Series A (2021): $50M with participation from RiverVest Venture Partners, OrbiMed, and U.S. Venture Partners
Private Equity (2025): $61.8M, investors not publicly disclosed
Series B (2025): $95M supported by US Venture Partners, RiverVest Venture Partners, RA Capital Management, Forbion, and OrbiMed
Key Investors in Sparrow Pharmaceuticals
RiverVest Venture Partners
RiverVest Venture Partners is a venture capital firm specializing in life sciences, aiming to build companies that address significant unmet medical needs and improve patient lives through science and innovation.
OrbiMed
OrbiMed Advisors LLC is an investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health, supporting companies from early-stage ventures to scaling organizations.
U.S. Venture Partners
U.S. Venture Partners (USVP) is a venture capital firm focused on early-stage investments in sectors including healthcare, enterprise software, and cybersecurity, collaborating with entrepreneurs to build transformative companies.
What's next for Sparrow Pharmaceuticals?
The recent major strategic investment positions Sparrow Pharmaceuticals for accelerated development and potential commercialization of its pipeline. This infusion of capital is expected to fuel further clinical trials, enhance research and development capabilities, and potentially expand the company's therapeutic focus. Sparrow Pharmaceuticals is poised to leverage this financial backing to navigate the complex regulatory pathways and market entry strategies inherent in the biopharmaceutical sector, aiming to establish itself as a key player in metabolic disease treatment.
See full Sparrow Pharmaceuticals company page
